系统性硬化症纤维化性肌病与更高死亡率相关
该回顾性横断面研究纳入37例伴肌无力的系统性硬化症(SSc)患者,按肌活检分为纤维化性肌病组(8例)和炎症性肌病组(29例)。纤维化性肌病组肌酸激酶和醛缩酶水平显著更低,但死亡率显著更高(62.5% vs 14.3%,P=0.005)。
要点
- SSc肌活检纯纤维化而无炎症/坏死为纤维化性肌病,属独特组织学亚型。
- 纤维化性肌病组CK和醛缩酶水平显著低于炎症性肌病组。
- 纤维化性肌病组死亡率显著高于炎症性肌病组(62.5% vs 14.3%)。
核心结论
- 纤维化性肌病是伴肌无力SSc患者中独特的肌肉病理亚型,与显著更差的死亡率相关。
研究设计与样本
- 回顾性横断面研究,纳入37例伴肌无力且有肌活检的SSc患者,按活检分为纤维化性肌病8例和炎症性肌病29例。
主要发现
- 纤维化性肌病组弥漫性SSc皮肤亚型占87% vs 62%(P=0.18),非裔美国人占62.5% vs 37.9%(P=0.20)。
- 纤维化性肌病组平均±SD用力肺活量为55.5±31.9 vs 66.4±17.6(P=0.23)。
- 纤维化性肌病组平均±SD肌酸激酶为516±391 vs 2477±3511 IU/L(P=0.007)。
- 纤维化性肌病组平均±SD醛缩酶为13.8±4.7 vs 27.3±4.7(P=0.01)。
- 纤维化性肌病组死亡5/8(62.5%)vs 炎症性肌病组4/29(14.3%),P=0.005。
临床怎么用
- 对伴肌无力的SSc患者应重视肌活检,识别纤维化性肌病亚型以评估预后。
- 纤维化性肌病患者CK和醛缩酶较低,不能仅凭肌酶正常排除肌肉病变。
- 纤维化性肌病死亡率高,需加强随访和综合管理。
局限性
- 回顾性横断面设计,样本量小(37例),纤维化性肌病组仅8例。
- 部分临床比较的P值未达统计学显著(如皮肤亚型P=0.18、种族P=0.20、FVC P=0.23)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine if a unique subtype of scleroderma muscle disease exists by comparing the clinical features of systemic sclerosis (SSc; scleroderma) patients with predominant fibrosis on muscle biopsy to those with inflammatory muscle histopathology. METHODS: This retrospective, cross-sectional study included SSc patients with muscle weakness and an available muscle biopsy. Biopsies with fibrosis but without inflammation/necrosis were designated as "fibrosing myopathy," and those with inflammation and/or necrosis were assigned a category of "inflammatory myopathy." Clinical data, including features of SSc, serum creatine kinase (CK) levels, electromyography, autoantibody profile, and survival, were compared between the 2 groups. RESULTS: The study population consisted of 37 weak SSc patients, 8 with fibrosing myopathy and 29 with inflammatory myopathy. Compared to those with inflammatory myopathy, patients with fibrosing myopathy were more likely to have diffuse SSc skin subtype (87% versus 62%; P = 0.18), African American race (62.5% versus 37.9%; P = 0.20), and a lower mean ± SD forced vital capacity (55.5 ± 31.9 versus 66.4 ± 17.6; P = 0.23). They also had lower mean ± SD CK values (516 ± 391 versus 2,477 ± 3,511 IU/liter; P = 0.007) and lower aldolase values (13.8 ± 4.7 versus 27.3 ± 4.7; P = 0.01). Patients with fibrosing myopathy had a significantly higher mortality (5 of 8 [62.5%] versus 4 of 29 [14.3%]; P = 0.005). CONCLUSION: Fibrosing myopathy is a unique histologic subtype of muscle disease among weak patients with SSc and is associated with significantly worse mortality compared to those with inflammation and/or necrosis on muscle biopsy.
引用
- Paik JJ, Wigley FM, Shah AA, et al. Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality. Arthritis Care Res (Hoboken). 2017. PMID: 28544788. doi:10.1002/acr.23291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。